Analyst Reco. Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
8.2 ^USD	+6.91%		+12.02%	+26.15%

04-30	RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	MT
04-29	Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	04-30	MT
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating	03-11	MT
Craig-Hallum Adjusts Avid Bioservices' Price Target to $16 From $22, Maintains Buy Rating	12-08	MT
KeyBanc Cuts Price Target on Avid Bioservices to $14 From $20, Maintains Overweight Rating	12-08	MT
RBC Cuts Price Target on Avid Bioservices to $7 From $15, Cites Slower Revenue Growth Assumptions Amid 'Challenging' Demand Backdrop; Outperform Kept	12-08	MT
William Blair Initiates Coverage on Avid Bioservices with Market Perform Rating	28/09/23	MT
RBC Cuts Price Target on Avid Bioservices to $15 From $17 Amid 'Mixed' Fiscal Q1 Results, Keeps Outperform Rating	08/09/23	MT
Stephens Adjusts Avid Bioservices Price Target to $20 From $24, Maintains Overweight Rating	22/06/23	MT
Craig Hallum Adjusts Avid Bioservices Price Target to $22 From $25, Maintains Buy Rating	22/06/23	MT
RBC Cuts Price Target on Avid Bioservices to $17 From $20, Cites Softer-Than-Expected Revenue Guidance; Outperform Kept	22/06/23	MT
Avid Bioservices Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $20 After Fiscal Q3 Beat; Shares Up Pre-Bell	14/03/23	MT
RBC Cuts Price Target on Avid Bioservices to $20 From $22, Notes Fiscal Q2 Adjusted EBITDA Miss, Keeps Outperform Rating	07/12/22	MT
RBC Cuts Price Target on Avid Bioservices to $22 From $32, Citing Lower Group Multiples, Maintains Outperform Rating	30/06/22	MT
Craig-Hallum Lowers Price Target for Avid Bioservices to $30 From $35, Maintains Buy Rating	09/03/22	MT
Stephens Adjusts Avid Bioservices' Price Target to $28 from $31, Keeps Overweight Rating	09/03/22	MT
Craig-Hallum Adjusts Price Target on Avid Bioservices to $35 From $29, Keeps Buy Rating	08/12/21	MT
RBC Lifts Price Target on Avid Bioservices to $32 From $27, Calls Fiscal Q2 'Impressive Quarter for New Business Wins,' Keeps Outperform	08/12/21	MT
KeyBanc Downgrades Avid Bioservices to Sector Weight From Overweight	08/12/21	MT
AVID BIOSERVICES : Craig-Hallum Adjusts Price Target on Avid Bioservices to $29 From $21, Maintains Buy Rating	30/06/21	MT
AVID BIOSERVICES : KeyBanc Adjusts Avid Bioservices' Price Target to $28 From $22, Reiterates Overweight Rating	30/06/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Analyst Reco.

Filters